21st April 2020

| To | To |
|---|---|
| Listing Department,<br>**NATIONAL STOCK EXCHANGE OF INDIA LIMITED**<br>Exchange Plaza,<br>Bandra Kurla Complex, Bandra (E),<br>**MUMBAI -400 051**<br><br>**Company Code No. AUROPHARMA** | The Corporate Relations Department<br>**BSE LIMITED**<br>Phiroz Jeejeebhoy Towers,<br>25th floor, Dalal Street,<br>**MUMBAI -400 001**<br><br>**Company Code No. 524804** |

Dear Sirs,

**Re: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**Sub: Update on Unit IV inspection conducted between Nov 4th -13th, 2019**

**Dear Sir/Mam,**

Further to our intimations dated 13th November 2019, 19th February and 21st February 2020 with regard to the inspection of Unit IV, an injectable manufacturing formulation facility of the Company, conducted between Nov 4th-13th, 2019, we would like to inform that US FDA has determined that the inspection classification of this facility is Voluntary Action Indicated (VAI).

Please take the above information on record.

Thanking you,

Yours faithfully,
**For AUROBINDO PHARMA LIMITED**

**B.Adi Reddy**
**Company Secretary**